The estimated Net Worth of Gordon R Bernard is at least $696 Тысяча dollars as of 20 September 2019. Gordon Bernard owns over 11,570 units of Cumberland Pharmaceuticals stock worth over $1,350 and over the last 15 years he sold CPIX stock worth over $694,522. In addition, he makes $0 as Independent Director at Cumberland Pharmaceuticals.
Gordon has made over 14 trades of the Cumberland Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 1,000 units of CPIX stock worth $4,790 on 6 December 2019.
The largest trade he's ever made was selling 21,640 units of Cumberland Pharmaceuticals stock on 28 May 2019 worth over $135,899. On average, Gordon trades about 4,759 units every 113 days since 2010. As of 20 September 2019 he still owns at least 1,000 units of Cumberland Pharmaceuticals stock.
You can see the complete history of Gordon Bernard stock trades at the bottom of the page.
Dr. Gordon R. Bernard M.D. serves as Independent Director of the Company. Dr. Bernard served as our Medical Director from 1999 until 2010 and currently serves as Chair of our Medical Advisory Board. He has served on our board of directors since 2010. Dr. Bernard is the Executive Vice President for Research at Vanderbilt University Medical Center, and also the Melinda Owen Bass Professor of Medicine and former Chief of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt. In addition, he is Executive Vice President for Research, Senior Associate Dean for Clinical Sciences and Chairman of Vanderbilt’s Pharmacy and Therapeutics Committee, which is responsible for approving the Vanderbilt Medical Center Formulary of approved drugs and therapeutics. Dr. Bernard has been conducting national and international trials of pharmaceuticals since 1980 and he has been steering committee chair of the National Institutes of Health, Acute Respiratory Distress Syndrome Clinical Trials Network since its inception in 1994 through its conclusion in 2014. This network is the only federally supported ongoing system for the conduct of research in the hospital Intensive Care Unit, or ICU. He holds a B.S. from the University of Southwestern Louisiana and an M.D. from Louisiana State University. Dr. Bernard maintains an active practice as an Intensivist in the Medical ICU at Vanderbilt and is therefore in a position to observe, first hand, the pharmaceutical management issues surrounding the care of a wide variety of the most severely ill patients and identify their unmet medical needs. The Board of Directors believes Dr. Bernard’s medical background is extremely valuable as the Company seeks to continue expanding its pipeline with promising products that offer advancement to patient care and are well-positioned competitively.
Gordon Bernard is 68, he's been the Independent Director of Cumberland Pharmaceuticals since 2010. There are 6 older and 12 younger executives at Cumberland Pharmaceuticals. The oldest executive at Cumberland Pharmaceuticals Inc. is Jonathan Griggs, 85, who is the Independent Director.
Gordon's mailing address filed with the SEC is 2525 WEST END AVE., SUITE 950, NASHVILLE, TN, 37203.
Over the last 15 years, insiders at Cumberland Pharmaceuticals have traded over $4,393,644 worth of Cumberland Pharmaceuticals stock and bought 265,077 units worth $1,208,228 . The most active insiders traders include Joey A Jacobs, Leo Pavliv и Thomas R Lawrence. On average, Cumberland Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $10,407. The most recent stock trade was executed by Caroline Young on 1 December 2022, trading 379 units of CPIX stock currently worth $849.
cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.
Cumberland Pharmaceuticals executives and other stock owners filed with the SEC include: